Tag Archives: transparency

Behind the China Bribery Scandals

The last few weeks have seen the media swamped with stories about the rampant bribery clawing the pharmaceutical industry in China. Big names were engulfed in the scandal, including GSK, AstraZeneca, Sanofi, Novartis, Eli Lilly, Novo Nordisk and UCB amongst others. Last month, four GSK executives were put under investigation for allegedly paying up to […]
Posted in Emerging Markets, Global, Guest Blog | Also tagged , , , , , , , , | Leave a comment

CMS taps IT firm CGI for Sunshine Act Data Dump

Speaking at CBI’s Sunshine & Aggregate Spend Conference in Washington DC on Tuesday, Shantanu Agrawal, director, data sharing and partnership group, center for program integrity, CMS, said the agency hired IT company CGI to build the software platform to be used for publishing pharma payments to physicians under the Sunshine Act provisions, now re-branded “open […]
Posted in Agency Insight, Deals, E-Media, FDA, healthcare, People, Technology | Also tagged , , , , , , , , , , , , , , | Leave a comment

FT Healthcare Conference: Society as Stakeholder

Speakers at the 2nd annual Financial Times US Healthcare and Life Sciences conference in New York last week discussed the cost of health, and the implications of an increasingly vocal and influential stakeholder group: the local populace. After opening remarks from Andrew Jack, FT’s prolific pharmaceuticals correspondent, Pfizer CEO Ian Read took the stage at […]
Posted in Europe, Events, Global, healthcare, leadership, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Strategy, Technology | Also tagged , , , , , , , , , , , , , , , , | Leave a comment

"Sunshine" Just the Tip of the Iceberg: Pharma and Full Disclosure

“Sunshine” Just the Tip of the Iceberg: Full Disclosure for Pharma:??There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices, writes Jill Wechsler. Although recent legislation and regulations have greatly expanded the range of information that pharmaceutical companies have to unveil to the public, there’s an […]
Posted in Guest Blog, healthcare, Op-Ed, pricing, Regulatory, Safety, Strategy | Also tagged , , , | 1 Comment

The Year to Come: EMA's Plans Announced

At the end of last month, the European Medicines Agency approved its budget and work program for the coming year, promising to implement measures to increase operational efficiency, enhance transparency and communication with stakeholders, and improve the quality and consistency of rulemaking. With a 4.1% increase in budget to €231.6 million and an anticipated 54 […]
Posted in Europe, Regulatory, Safety, Strategy | Also tagged , , | Leave a comment
  • Categories

  • Meta